Table 3.
Median survival time by stratification factor in patients with advanced biliary tract cancer treated with gemcitabine plus S‐1 combination therapy (GS) or S‐1 alone
| GS | S‐1 | Total | |
|---|---|---|---|
| Tumor site | |||
| GB (n = 38) | 11.7 (6.3–13.9) | 6.5 (3.6–8.0) | 7.9 (6.3–11.1) |
| Non‐GB (n = 63) | 15.0 (7.7–20.6) | 14.3 (8.0–23.3) | 15.0 (9.9–20.6) |
| Stage | |||
| Stage II, III (n = 15) | 13.0 (5.9–NE) | 14.3 (2.1–NE) | 13.9 (7.3–NE) |
| Stage IV (n = 61) | 10.6 (6.3–15.4) | 7.5 (5.6–10.0) | 8.0 (6.9–10.6) |
| Recurrence (n = 25) | 19.1 (7.6–NE) | 17.0 (6.2–21.3) | 17.0 (11.7–21.3) |
Data are shown as the median (95% confidence interval). GB, gallbladder; NE, not estimable.